The impact of COVID-19 on medical insurers across European countries will vary significantly depending on factors like the profile of infection rates and hospital capacity in each country. However, based on some discussion with insurers across countries and initial modelling there are a number of common themes across Europe including underwriting risk, market and counterparty risk, and operational risks. Milliman’s Joanne Buckle explores these themes and others in her article “How will COVID-19 affect European medical insurers?”
Under Solvency II, European insurers are required to publish their Solvency and Financial Condition Reports (SFCRs). Two sets of SFCRs have been published, with the first publication for most entities occurring in May 2017 and the second one in May 2018.
The SFCRs contain a significant amount of information including details of the company’s performance over the reporting period, system of governance, risk profile, valuation basis and capital requirements. In addition, the SFCRs include a number of Quantitative Reporting Templates (QRTs) providing details of the company’s financial position under Solvency II.
This analysis by Milliman consultants compares information provided in the QRTs and SFCRs and draws conclusions about the balance sheets and risk exposures of European health insurers. It also highlights substantial trends between the 2017 and 2018 publications.
A key focus of the insurance regulatory authorities around the world has been the protection of policyholder interest. This has resulted in more emphasis on product governance and product life-cycle management. The insurance directive launched under the European Union insurance law has issued guidelines for insurers to embed product oversight and governance into their risk management frameworks.
A robust product governance process can help reduce mis-selling and complaints, and increase policyholder confidence in the market. It can also ensure internal and regulatory compliance for the products offered by the insurer.
The core components of a robust product governance process are:
• Product governance policy
• Product development
• Pricing and value
• Distribution and sales
• Legal, compliance and risk management
• Ongoing assessment of the product
To read more about building a strong product governance policy, read Neha Taneja’s article here.